The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
­­­­­­Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results.
 
Samuel A Funt
Employment - ByHeart (I)
Stock and Other Ownership Interests - 76Bio (I); Allogene Therapeutics; Doximity; IconOVir Bio (I); Kite, a Gilead company; Kronos Bio; Neogene Therapeutics (I); Urogen pharma (I); Vida Ventures (I)
Consulting or Advisory Role - BioNtech; Immunai; Merck
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Decibel Therapeutics (Inst); Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb
 
Petros Grivas
Consulting or Advisory Role - AADi; Abbvie; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; BostonGene; Bristol-Myers Squibb; CG Oncology; EMD Serono; Fresenius Kabi; G1 Therapeutics; Gilead Sciences; ImmunityBio; Janssen; Lucence; Merck; Pfizer; PureTech; Roche; Seagen; Silverback Therapeutics; Strata Oncology
Research Funding - Acrivon Therapeutics (Inst); ALX Oncology (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Xin Gao
Consulting or Advisory Role - Arvinas; Bayer; Flare Therapeutics; Loxo/Lilly; PATHAI; PureTech; Silverback Therapeutics
Research Funding - ALX Oncology (Inst); Aprea Therapeutics (Inst); Aravive (Inst); Arvinas (Inst); Bayer (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Poseida therapeutics (Inst); Regeneron (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst)
 
Daniel A. Vaena
Honoraria - HMP; OncLive; OneOncology; Total Health Conferencing
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Cardinal Health; Curio/Vaniam Group; DAVA Pharmaceuticals; Eisai; EMD Serono; Exelixis; Gilead Sciences; IntrinsiQ; Janssen; MJH Life Sciences; Sanofi; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Exelixis (Inst); Merck (Inst); OBI Pharma (Inst); Roche/Genentech (Inst); Seagen (Inst); Tallac Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Tempus
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Aptitude Health; Caris Life Sciences; Clinical Care Options; Curio Science; MJH Life Sciences; Peerview
Consulting or Advisory Role - Aravive; AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Gilead Sciences; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi/Aventis; Seagen
Research Funding - ALX Oncology (Inst); Exelixis (Inst); Loxo/Lilly (Inst); OncoC4; Pfizer (Inst); Tempus (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Bayer; Janssen
Other Relationship - ASCO; Kidney Cancer Association; KidneyCan; Myrovlytis Trust
 
Matthew I. Milowsky
Stock and Other Ownership Interests - Gilead Sciences; Merck; Pfizer
Consulting or Advisory Role - Loxo/Lilly
Research Funding - Accuray (Inst); Acrivon Therapeutics (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance Foundation Trials (Inst); ALX Oncology (Inst); Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); G1 Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Incyte (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); PCCTC (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Elsevier; Medscape; Research to Practice
 
Mayank Rao
Employment - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology
 
Harry Liu
Employment - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology
 
Kimberly Tipton
Employment - ALX Oncology
 
Grace An
Employment - ALX Oncology
 
Feng Jin
Consulting or Advisory Role - ALX Oncology
 
Alison J Forgie
Employment - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology
 
Sophia Randolph
Employment - ALX Oncology
Stock and Other Ownership Interests - Carrick Therapeutics; Pfizer
 
Athanasios C. Tsiatis
Employment - ALX Oncology
Stock and Other Ownership Interests - ALX Oncology
Patents, Royalties, Other Intellectual Property - ALX Oncology (Inst); Genomic Health-Proprietary (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - ALX Oncology
 
Rohit K. Jain
Honoraria - Curio Science; DAVA Oncology; FLASCO; MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Sanofi
Speakers' Bureau - Seattle Genetics/Astellas
Research Funding - Bristol Myers Squibb; Gilead Sciences; NCI
Travel, Accommodations, Expenses - DAVA Oncology; FLASCO; Sanofi